Flexion Therapeutics, Inc. (NASDAQ:FLXN) insider Yamo Deniz bought 3,000 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was bought at an average cost of $24.15 per share, for a total transaction of $72,450.00. Following the transaction, the insider now owns 5,000 shares of the company’s stock, valued at approximately $120,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Yamo Deniz also recently made the following trade(s):

  • On Tuesday, September 5th, Yamo Deniz bought 1,000 shares of Flexion Therapeutics stock. The stock was bought at an average cost of $24.20 per share, for a total transaction of $24,200.00.
  • On Thursday, August 31st, Yamo Deniz bought 1,375 shares of Flexion Therapeutics stock. The stock was bought at an average cost of $25.40 per share, for a total transaction of $34,925.00.

Shares of Flexion Therapeutics, Inc. (NASDAQ FLXN) traded up 2.16% during midday trading on Friday, hitting $24.12. The stock had a trading volume of 732,733 shares. The company’s market cap is $769.55 million. The stock’s 50-day moving average price is $23.24 and its 200 day moving average price is $21.99. Flexion Therapeutics, Inc. has a 52 week low of $15.88 and a 52 week high of $29.41.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.11). On average, equities analysts forecast that Flexion Therapeutics, Inc. will post ($3.70) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/09/15/flexion-therapeutics-inc-flxn-insider-buys-72450-00-in-stock.html.

Several hedge funds have recently modified their holdings of the company. Macquarie Group Ltd. increased its stake in shares of Flexion Therapeutics by 0.6% during the 2nd quarter. Macquarie Group Ltd. now owns 55,917 shares of the specialty pharmaceutical company’s stock worth $1,131,000 after purchasing an additional 338 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Flexion Therapeutics by 0.5% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 101,214 shares of the specialty pharmaceutical company’s stock worth $2,047,000 after purchasing an additional 513 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Flexion Therapeutics by 3.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,802 shares of the specialty pharmaceutical company’s stock worth $441,000 after purchasing an additional 811 shares during the last quarter. ProShare Advisors LLC increased its stake in shares of Flexion Therapeutics by 5.5% during the 2nd quarter. ProShare Advisors LLC now owns 18,750 shares of the specialty pharmaceutical company’s stock worth $379,000 after purchasing an additional 982 shares during the last quarter. Finally, IFP Advisors Inc increased its stake in shares of Flexion Therapeutics by 24.5% during the 2nd quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after purchasing an additional 1,000 shares during the last quarter. Institutional investors own 82.75% of the company’s stock.

A number of research firms recently issued reports on FLXN. Royal Bank Of Canada set a $44.00 target price on Flexion Therapeutics and gave the company a “buy” rating in a research report on Monday. ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. Northland Securities began coverage on Flexion Therapeutics in a research report on Thursday, August 24th. They issued an “outperform” rating and a $40.00 target price on the stock. Finally, BMO Capital Markets reaffirmed a “buy” rating on shares of Flexion Therapeutics in a research report on Friday, August 11th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $31.50.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.